Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

One milestone down
September 2019
SHARING OPTIONS:

CAMBRIDGE, U.K.—As announced by Horizon Discovery Group plc, biopharmaceutical company Celyad recently had its IND application accepted by the FDA for the autologous NKG2D based CAR-T cell therapy CYAD-02, which utilizes Horizon’s optimized SMARTvector shRNA technology. The successful IND filing has triggered an undisclosed milestone payment to Horizon. A Phase 1 dose-escalation trial assessing the safety and clinical activity of CYAD-02 is planned for early next year, and will feature a preconditioning chemotherapy (CyFlu) in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndromes.
 
“We see great potential for shRNA technology in the optimization of next-generation cell therapies. The success of this IND filing is testament to the strength of our relationship with Celyad, and the powerful combination of Horizon’s SMARTvector shRNA platform with Celyad’s CAR-T expertise,” said Terry Pizzie, CEO of Horizon.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.